The legal battle over the marketing practices surrounding the epilepsy drug Neurontin and its off-label uses has major pharmaceutical companies waiting anxiously for a decision. The suit claims Parke-Davis, now part of Pfizer, engaged in illegal off-label promotion, and a victory for the plaintiff could lead to investigations of other drug companies' practices in the off-label area and force companies to look closely at their compliance and training practices. Some say the federal government is interested in a crackdown on off-label uses to cut its costs under the new Medicare prescription drug law.

Related Summaries